Quick Answer
Niagen Bioscience, Inc. reported Diluted EPS of $0.20 per share for fiscal year 2025.
Niagen Bioscience, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.20 | +81.8% |
| 2024 | $0.11 | +257.1% |
| 2023 | -$0.07 | +70.8% |
| 2022 | -$0.24 | +40.0% |
| 2021 | -$0.40 | -21.2% |
| 2020 | -$0.33 | -175.0% |
| 2011 | -$0.12 | -200.0% |
| 2010 | -$0.04 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.05 | +150.0% | +25.0% |
| June 30, 2025 | $0.04 | — | -33.3% |
| March 31, 2025 | $0.06 | +700.0% | +200.0% |
| September 30, 2024 | $0.02 | +300.0% | — |
| June 30, 2024 | $0.00 | +100.0% | +100.0% |
| March 31, 2024 | -$0.01 | +66.7% | +0.0% |
| September 30, 2023 | -$0.01 | +0.0% | +66.7% |
| June 30, 2023 | -$0.03 | +66.7% | +0.0% |
- Niagen Bioscience, Inc. showed an increase of +81.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2010–2025 period, Niagen Bioscience, Inc.’s diluted eps has grown by 600.0% (from $0.04 per share (loss) to $0.20 per share).
- The most recent figure is from Niagen Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: